RxDoctor Payments Data

Anu Duvoor, MD

Internal Medicine · Clinton Twp, MINPI 1528089497

Payments from drug & device makers

$5,851in general payments, 2019–2025

Across 340 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$826
  • Johnson & Johnson$455
  • GSK$451
  • Novo Nordisk$380
  • AbbVie$334
  • AstraZeneca$269
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,851 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$173,504
Medicare patients
320
Services billed
1,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$79,812
OzempicSemaglutide37$59,996
JardianceEmpagliflozin33$56,576
FarxigaDapagliflozin Propanediol50$44,597
InvokanaCanagliflozin22$35,418
JanuviaSitagliptin Phosphate20$31,563
XareltoRivaroxaban31$30,121
RybelsusSemaglutide20$28,347
Repatha SureclickEvolocumab17$21,934
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$12,885
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$6,874
Atorvastatin Calcium354$5,609
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$4,068
Novolog FlexpenInsulin Aspart32$3,723
Levothyroxine Sodium210$2,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$380$88,34357 claims
PfizerEliquis$149$79,81274 claims
Boehringer IngelheimJardiance, Stiolto Respimat$190$69,46254 claims
Johnson & JohnsonInvokana, Xarelto$455$65,53953 claims
AstraZenecaFarxiga, Symbicort$269$46,71862 claims
MerckJanuvia$19$31,56320 claims
AbbVieSynthroid$334$1,19019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Clinton Twp

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →